Last edition
News about "Pulmonary Embolism (PE)"
Argo Biopharma Doses First Patient in Phase 1 siRNA Trial
Argo Biopharma has dosed the first participant in the phase I trial of BW-41012, its Factor XI-targeting siRNA therapy for preventing thromboembolic diseases.
Pulmonary Embolism (PE) | 22/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members